Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,122 stopped studies mapped to Lung Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,122 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05840770 | Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small… | Phase 2 | withdrawn | May 3, 2023 | City of Hope Medical Center | no accrual | Enrollment / accrual |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT02093962 | Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous… | Phase 2 | terminated | Mar 21, 2014 | ImmunoGenesis | At the interim analysis, the futility boundary was not met and the study was stopped due to… | Efficacy / futility |
| NCT04427072 | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated…(GeoMETry-III) | Phase 3 | terminated | Jun 11, 2020 | Novartis Pharmaceuticals | Company decision not related to any safety concerns. | Safety / toxicity |
| NCT03877250 | Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies | — | withdrawn | Mar 15, 2019 | Memorial Sloan Kettering Cancer Center | The primary objectives have not been met due to no patient enrollment therefore, the PI is… | Enrollment / accrual |
| NCT02521051 | Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic… | Phase 1 / Phase 2 | terminated | Aug 13, 2015 | Massachusetts General Hospital | slow accrual | Enrollment / accrual |
| NCT05374538 | VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant… | Phase 1 | terminated | May 16, 2022 | Vitrac Therapeutics, LLC | Sponsor decision | Sponsor / business decision |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients… | Phase 1 | terminated | Mar 7, 2023 | Coherus Oncology, Inc. | The study was terminated for strategic reasons (not for safety concerns) | Safety / toxicity |
| NCT05840510 | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and… | Phase 1 | terminated | May 3, 2023 | Mirati Therapeutics Inc. | Business objectives have changed | Sponsor / business decision |
| NCT05275673 | A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous… | Phase 2 | terminated | Mar 11, 2022 | Faeth Therapeutics | Sponsor decision - funding issues | Funding |
| NCT06522360 | Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced… | Phase 2 | withdrawn | Jul 26, 2024 | M.D. Anderson Cancer Center | 0 participants enrolled | Enrollment / accrual |
| NCT04892472 | EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields…(KEYNOTE B36) | Phase 2 | terminated | May 19, 2021 | NovoCure GmbH | Phase 2 study terminated due to insufficient enrollment and was not based on safety concerns.… | Safety / toxicity |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid… | Phase 1 / Phase 2 | terminated | May 6, 2021 | NextCure, Inc. | Due to the limited activity in Phase 1, NextCure decided to discontinue development of the… | Other (stated, no rule matched) |
| NCT05790460 | Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients…(TESTING) | N/A | terminated | Mar 30, 2023 | Abramson Cancer Center at Penn Medicine | Insufficient accrual | Enrollment / accrual |
| NCT04485026 | Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma | Phase 2 | withdrawn | Jul 24, 2020 | Wake Forest University Health Sciences | No enrollments, low patient population as well as a dramatic change in the insurance approval… | Enrollment / accrual |
| NCT04870112 | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer…(SCope-D1) | Phase 1 | terminated | May 3, 2021 | AstraZeneca | AstraZeneca has decided to stop further enrollment and the study was terminated when all patients… | Safety / toxicity |
| NCT04925986 | Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+… | Phase 2 | terminated | Jun 14, 2021 | Sarah Goldberg | Sponsor decision based on data from other clinical trials | Sponsor / business decision |
| NCT06094296 | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With… | Phase 2 | terminated | Oct 23, 2023 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT02974725 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | Phase 1 | terminated | Nov 28, 2016 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT05648188 | A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells(LUNGadenosine) | — | withdrawn | Dec 13, 2022 | Centre Hospitalier Universitaire de Nice | no patients enrolled | Enrollment / accrual |
| NCT05737706 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Phase 1 | terminated | Feb 21, 2023 | Mirati Therapeutics Inc. | Formulation challenges | Other (stated, no rule matched) |
| NCT02973763 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced… | Phase 1 | terminated | Nov 25, 2016 | Allist Pharmaceuticals, Inc. | Indications have been approved for marketing | Other (stated, no rule matched) |
| NCT03127449 | AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | N/A | terminated | Apr 25, 2017 | Allist Pharmaceuticals, Inc. | Indications have been approved for marketing | Other (stated, no rule matched) |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT04512430 | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | Phase 2 | terminated | Aug 13, 2020 | Fundación GECP | Low recruitment | Enrollment / accrual |
| NCT04786964 | Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line…(CONTERNO) | Phase 3 | terminated | Mar 8, 2021 | Checkpoint Therapeutics, Inc. | Regional political conflict | Other (stated, no rule matched) |
| NCT05911308 | Abequolixron (RGX-104) and Durvalumab in Lung Cancer | Phase 1 | terminated | Jun 22, 2023 | UNC Lineberger Comprehensive Cancer Center | Sponsor is closing the trial. | Other (stated, no rule matched) |
| NCT04990479 | Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma | Phase 1 | terminated | Aug 4, 2021 | Nouscom SRL | Terminated by Sponsor | Other (stated, no rule matched) |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in… | — | withdrawn | May 17, 2021 | Pfizer | The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug supply |
| NCT05543629 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and… | Phase 1 / Phase 2 | terminated | Sep 16, 2022 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT04316013 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial | Phase 3 | terminated | Mar 20, 2020 | Peter MacCallum Cancer Centre, Australia | Not meeting recruitment timelines | Enrollment / accrual |
| NCT04958967 | Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation | Phase 1 | withdrawn | Jul 12, 2021 | Allist Pharmaceuticals, Inc. | The protocol need to review | Other (stated, no rule matched) |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | Phase 2 | terminated | Nov 16, 2020 | Incyte Corporation | Strategic business decision to terminate the study effective immediately. This is due to a company… | Sponsor / business decision |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04032847 | ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC | Phase 1 / Phase 2 | terminated | Jul 25, 2019 | Achilles Therapeutics UK Limited | Sponsor decision | Sponsor / business decision |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | Phase 1 | terminated | Oct 12, 2022 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT00503971 | Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR… | Phase 1 / Phase 2 | terminated | Jul 19, 2007 | Spanish Lung Cancer Group | not stated | Not stated |
| NCT00979576 | BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 1 | terminated | Sep 18, 2009 | Boehringer Ingelheim | not stated | Not stated |
| NCT03496766 | Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS | Phase 2 | terminated | Apr 12, 2018 | Spanish Lung Cancer Group | The recruitment was closed prematurely to due to slow recruitment. | Enrollment / accrual |
| NCT04495894 | Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer… | Phase 2 | terminated | Aug 3, 2020 | Emory University | This study was terminated after interim analyses showed no benefits. | Efficacy / futility |
| NCT03169738 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy… | Phase 1 / Phase 2 | withdrawn | May 30, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03574649 | QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT… | Phase 2 | withdrawn | Jul 2, 2018 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT02231164 | LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With… | Phase 3 | terminated | Sep 4, 2014 | Boehringer Ingelheim | not stated | Not stated |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | Phase 1 | terminated | Apr 28, 2021 | Blueprint Medicines Corporation | Sponsor decision, not related to safety concerns | Safety / toxicity |
| NCT05229900 | A Study of SGN-ALPV in Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05241873 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | Phase 1 | terminated | Feb 16, 2022 | Blueprint Medicines Corporation | Sponsor decision, not related to safety concerns | Safety / toxicity |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | Phase 1 | terminated | Dec 14, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05407038 | Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer… | N/A | terminated | Jun 7, 2022 | Mayo Clinic | Study stopped early due to enrollment challenges. | Enrollment / accrual |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small… | Phase 1 | terminated | Nov 30, 2022 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 26, 2025source: clinicaltrials